Aug. 12 at 2:11 PM
$OM (Grok agrees) 😉
In a take-private scenario, the lack of growth and ongoing losses would temper bidder enthusiasm, leading to a lower premium (~20%, down from prior estimates to align with distressed medtech deals like Baxter). This yields:
Price Per Share: Approximately
$14.77 (current
$12.31 + 20% premium; range:
$13.85–
$15.39 if bidding is competitive but capped by losses).
Total Acquisition Price (Equity Value Paid to Shareholders): Approximately
$262 million (range:
$246–
$273 million).
This implies an enterprise value of ~
$182 million (~1.0x TTM revenue, adjusted for the premium). The Baxter precedent boosts deal probability (e.g., as a home-dialysis add-on), but the no-growth/loss factors suggest a more opportunistic, lower-multiple transaction—potentially closer to a fire-sale if performance worsens. This is hypothetical; real offers would depend on Q3 results and market shifts.
